Bank Julius Baer & Co. Ltd, Zurich Viking Therapeutics, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 23, 2021	SELL	$5.19 - $6.73 $33,216 - $43,072	-6,400 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$5.74 - $9.67 $9,143 - $15,404	-1,593 Reduced 19.93%	6,400 $40,000
Q4 2020 Feb 24, 2021	SELL	$5.3 - $6.71 $37 - $46	-7 Reduced 0.09%	7,993 $45,000
Q4 2020 Feb 12, 2021	BUY	$5.3 - $6.71 $15,900 - $20,130	3,000 Added 60.0%	8,000 $45,000
Q2 2020 Aug 12, 2020	SELL	$4.35 - $8.08 $4 - $8	-1 Reduced 0.02%	5,000 $36,000
Q1 2020 May 13, 2020	BUY	$3.45 - $7.95 $17,253 - $39,757	5,001 New	5,001 $23,000

480

66.2M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.